| Project/Area Number |
18K15959
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | EGFR-TKI / 耐性化機序 / 非小細胞肺癌 |
|---|
| Outline of Final Research Achievements |
We collected samples through KLOG (Keio Lung Oncology Group). We esatablished a xenograft model subcutaneously transplanted with a non-small cell lung cancer cell line and lung cancer cells resistant to thrid generation EGFR-TKI. We reported new resistance mechanism to third generation EGFR-TKI.
|
| Academic Significance and Societal Importance of the Research Achievements |
肺癌では分子生物学的な解明が進められ、特定の遺伝子変異を持つ症例では分子標的薬が奏功し予後の延長が得られる。しかし、その耐性化が問題であり、未だ根治は困難である。EGFR遺伝子変異に対して第三世代EGFRチロシンキナーゼ阻害剤が有効だが、現時点では同薬剤に対する耐性化の克服ができていない。実際に耐性化した臨床検体を回収し耐性化機序を解明することは、肺癌患者の予後延長につながるため学術的、社会的意義は大きい。
|
